Submitted:
17 May 2024
Posted:
20 May 2024
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Methods and Materials
2.1. Overall Methodology Workflow
2.2. Receptor and Native Ligand Preparation and Docking Simulations
2.3. PFAS Preparation and Docking
2.4. Molecular Docking
3. Results and Discussion
3.1. Docking Verification: Cross-Docking of Known Ligands and Non-Native Ligands and Comparison with Experimental Binding Affinity
3.1.1. Cross-Docking of Known Ligands: VDR
3.1.2. Cross-Docking of Known Ligands: PPARγ
3.1.3. Cross-Docking of Known Ligands: PXR
3.1.4. Cross-Docking of Known Ligands: ER𝛼
3.1.5. Cross Docking of Non-native Ligands: VDR
3.1.6. Cross Docking of Nonnative Ligands: PPARγ
3.1.7. Cross Docking of Nonnative Ligands: PXR
3.1.8. Verification of Experimental Binding Affinity Values for Docking Accuracy
3.2. Virtual Screening of PFAS Molecules against VDR, PXR, PPARγ, and ER𝛼
3.2.1. PFAS Virtual Screening: VDR Orthosteric Site
3.2.2. PFAS Virtual Screening: VDR Allosteric Site
3.2.3. PFAS Virtual Screening: PPARγ Orthosteric Site
3.2.4. PFAS Virtual Screening: PPARγ Allosteric Site
3.2.4. PFAS Virtual Screening: PXR Orthosteric Site
3.2.5. PFAS Virtual Screening: PXR Allosteric Site
3.2.6. PFAS Virtual Screening: ER𝛼 Orthosteric Site
3.2.7. PFAS Virtual Screening: ER𝛼 Allosteric Site
3.3. Commercially Relevant PFAS Molecules Virtual Screening: VDR
3.3.1. Commercially Relevant PFAS Virtual Screening: VDR Orthosteric Site
3.3.2. Commercially Relevant PFAS Virtual Screening: VDR Allosteric Site
3.4. Modeling of PFAS Mixture
4. Strengths and Limitations
5. Future Directions
6. Conclusion
Supplementary Materials
Acknowledgments
References
- Pettersen, E.F.; Goddard, T.D.; Huang, C.C.; et al. UCSF ChimeraX: Structure visualization for researchers, educators, and developers. Protein Science 2021, 30, 70–82. [Google Scholar] [CrossRef] [PubMed]
- Morris, G.M.; Huey, R.; Lindstrom, W.; Sanner, M.F.; Belew, R.K.; Goodsell, D.S.; Olson, A.J. Autodock4 and AutoDockTools4: automated docking with selective receptor flexiblity. J. Computational Chemistry 2009, 16, 2785–2791. [Google Scholar] [CrossRef] [PubMed]
- Ropp, P.J.; Spiegel, J.O.; Walker, J.L. Gypsum-DL: an open-source program for preparing small-molecule libraries for structure-based virtual screening. J Cheminform 2019, 11, 34. [Google Scholar] [CrossRef]
- Goddard, T.D.; Huang, C.C.; Meng, E.C.; Pettersen, E.F.; Couch, G.S.; Morris, J.H.; Ferrin, T.E. UCSF ChimeraX: Meeting modern challenges in visualization and analysis. Protein Sci. 2018, 27, 14–25. [Google Scholar] [CrossRef]
- Jerome Eberhardt, Diogo Santos-Martins, Andreas, F. Tillack, and Stefano Forli Journal of Chemical Information and Modeling 2021, 61, 3891–3898. [CrossRef] [PubMed]
- Trott, O.; Olson, A.J. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 2010, 31, 455–461. [Google Scholar] [CrossRef] [PubMed]
- Pelch, K.E.; Reade, A.; Wolffe, T.A.M.; Kwiatkowski, C.F. PFAS health effects database: Protocol for a systematic evidence map. Environ Int. 2019, 130, 104851. [Google Scholar] [CrossRef] [PubMed]
- Domingo, J.L.; Nadal, M. Human exposure to per- and polyfluoroalkyl substances (PFAS) through drinking water: A review of the recent scientific literature. Environ Res. 2019, 177, 108648. [Google Scholar] [CrossRef]
- Ding, N.; Harlow, S.D.; Randolph JF Jr, Loch-Caruso, R. ; Park, S.K. Perfluoroalkyl and polyfluoroalkyl substances (PFAS) and their effects on the ovary. Hum Reprod Update. 2020, 26, 724–752. [Google Scholar] [CrossRef]
- Wang, Y.; Zhu, J.; DeLuca, H.F. Where is the vitamin D receptor? Arch Biochem Biophys. 2012, 523, 123–133. [Google Scholar] [CrossRef]
- Yang, R.; Chen, J.; Zhang, J.; Qin, R.; Wang, R.; Qiu, Y.; Mao, Z.; Goltzman, D.; Miao, D. 1,25-Dihydroxyvitamin D protects against age-related osteoporosis by a novel VDR-Ezh2-p16 signal axis. Aging Cell. 2020, 19, e13095. [Google Scholar] [CrossRef] [PubMed]
- Liang, L.; Pan, Y.; Bin, L.; Liu, Y.; Huang, W.; Li, R.; Lai, K.P. Immunotoxicity mechanisms of perfluorinated compounds PFOA and PFOS. Chemosphere. 2022, 291, 132892. [Google Scholar] [CrossRef] [PubMed]
- Azhagiya Singam, E.R.; Durkin, K.A.; La Merrill, M.A.; Furlow, J.D.; Wang, J.C.; Smith, M.T. The vitamin D receptor as a potential target for the toxic effects of per- and polyfluoroalkyl substances (PFASs): An in-silico study. Environmental research 2023, 217, 114832. [Google Scholar] [CrossRef] [PubMed]
- Boyd, R.I.; Ahmad, S.; Singh, R.; Fazal, Z.; Prins, G.S.; Madak Erdogan, Z.; Irudayaraj, J.; Spinella, M.J. Toward a Mechanistic Understanding of Poly- and Perfluoroalkylated Substances and Cancer. Cancers 2022, 14, 2919. [Google Scholar] [CrossRef] [PubMed]
- Goodrich, J.A.; Walker, D.; Lin, X.; Wang, H.; Lim, T.; McConnell, R.; Conti, D.V.; Chatzi, L.; Setiawan, V.W. Exposure to perfluoroalkyl substances and risk of hepatocellular carcinoma in a multiethnic cohort. JHEP reports : innovation in hepatology 2022, 4, 100550. [Google Scholar] [CrossRef] [PubMed]
- Fenton, S.E.; Ducatman, A.; Boobis, A.; DeWitt, J.C.; Lau, C.; Ng, C.; Smith, J.S.; Roberts, S.M. Per- and Polyfluoroalkyl Substance Toxicity and Human Health Review: Current State of Knowledge and Strategies for Informing Future Research. Environmental toxicology and chemistry 2021, 40, 606–630. [Google Scholar] [CrossRef]
- Lin, L.; Zhang, L.; Li, C.; Gai, Z.; Li, Y. Vitamin D and Vitamin D Receptor: New Insights in the Treatment of Hypertension. Current protein & peptide science 2019, 20, 984–995. [Google Scholar] [CrossRef] [PubMed]
- Di Nisio, A.; Rocca, M. S.; De Toni, L.; Sabovic, I.; Guidolin, D.; Dall'Acqua, S.; Acquasaliente, L.; De Filippis, V.; Plebani, M. , & Foresta, C. Endocrine disruption of vitamin D activity by perfluoro-octanoic acid (PFOA). Scientific reports 2020, 10, 16789. [Google Scholar] [CrossRef]
- Fragki, S.; Dirven, H.; Fletcher, T.; Grasl-Kraupp, B.; Bjerve Gützkow, K.; Hoogenboom, R.; Kersten, S.; Lindeman, B.; Louisse, J.; Peijnenburg, A.; Piersma, A.H.; Princen, H.M.G.; Uhl, M.; Westerhout, J.; Zeilmaker, M.J.; Luijten, M. Systemic PFOS and PFOA exposure and disturbed lipid homeostasis in humans: what do we know and what not? Crit Rev Toxicol. 2021, 51, 141–164. [Google Scholar] [CrossRef]
- von Holst, H.; Nayak, P.; Dembek, Z.; Buehler, S.; Echeverria, D.; Fallacara, D.; John, L. Perfluoroalkyl substances exposure and immunity, allergic response, infection, and asthma in children: review of epidemiologic studies. Heliyon. 2021, 7, e08160. [Google Scholar] [CrossRef]
- Tsuda, S. Differential toxicity between perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA). J Toxicol Sci. 2016, 41, SP27–SP36. [Google Scholar] [CrossRef] [PubMed]
- Tarapore, P.; Ouyang, B. Perfluoroalkyl Chemicals and Male Reproductive Health: Do PFOA and PFOS Increase Risk for Male Infertility? Int J Environ Res Public Health. 2021, 18, 3794. [Google Scholar] [CrossRef] [PubMed]
- Yao, B.; He, J.; Yin, X.; Shi, Y.; Wan, J.; Tian, Z. The protective effect of lithocholic acid on the intestinal epithelial barrier is mediated by the vitamin D receptor via a SIRT1/Nrf2 and NF-κB dependent mechanism in Caco-2 cells. Toxicol Lett. 2019, 316, 109–118. [Google Scholar] [CrossRef]
- van Gerwen, M.; Colicino, E.; Guan, H.; Dolios, G.; Nadkarni, G.N.; Vermeulen, R.C.H.; Wolff, M.S.; Arora, M.; Genden, E.M.; Petrick, L.M. Per- and polyfluoroalkyl substances (PFAS) exposure and thyroid cancer risk. EBioMedicine. 2023, 97, 104831. [Google Scholar] [CrossRef] [PubMed]
- Mukherjee, S.; Balius, T.E.; Rizzo, R.C. Docking validation resources: protein family and ligand flexibility experiments. J Chem Inf Model. 2010, 50, 1986–2000. [Google Scholar] [CrossRef] [PubMed]
- Pierozan, P.; Kosnik, M.; Karlsson, O. High-content analysis shows synergistic effects of low perfluorooctanoic acid (PFOS) and perfluorooctane sulfonic acid (PFOA) mixture concentrations on human breast epithelial cell carcinogenesis. Environ Int. 2023, 172, 107746. [Google Scholar] [CrossRef] [PubMed]
- Wu, B.; Pan, Y.; Li, Z.; Wang, J.; Ji, S.; Zhao, F.; Chang, X.; Qu, Y.; Zhu, Y.; Xie, L.; Li, Y.; Zhang, Z.; Song, H.; Hu, X.; Qiu, Y.; Zheng, X.; Zhang, W.; Yang, Y.; Gu, H.; Li, F.; Cai, J.; Zhu, Y.; Cao, Z.; S Ji, J.; Lv, Y.; Dai, J.; Shi, X. Serum per- and polyfluoroalkyl substances and abnormal lipid metabolism: A nationally representative cross-sectional study. Environ Int. 2023, 172, 107779. [Google Scholar] [CrossRef]
- Ishizawa, M.; Akagi, D.; Makishima, M. Lithocholic Acid Is a Vitamin D Receptor Ligand That Acts Preferentially in the Ileum. Int J Mol Sci. 2018, 19, 1975. [Google Scholar] [CrossRef] [PubMed]
- Shearer, J.J.; Callahan, C.L.; Calafat, A.M.; Huang, W.Y.; Jones, R.R.; Sabbisetti, V.S.; Freedman, N.D.; Sampson, J.N.; Silverman, D.T.; Purdue, M.P.; Hofmann, J.N. Serum Concentrations of Per- and Polyfluoroalkyl Substances and Risk of Renal Cell Carcinoma. J Natl Cancer Inst. 2021, 113, 580–587. [Google Scholar] [CrossRef]
- Rhee, J.; Chang, V.C.; Cheng, I.; Calafat, A.M.; Botelho, J.C.; Shearer, J.J.; Sampson, J.N.; Setiawan, V.W.; Wilkens, L.R.; Silverman, D.T.; Purdue, M.P.; Hofmann, J.N. Serum concentrations of per- and polyfluoroalkyl substances and risk of renal cell carcinoma in the Multiethnic Cohort Study. Environ Int. 2023, 180, 108197. [Google Scholar] [CrossRef]
- Purdue, M.P.; Rhee, J.; Denic-Roberts, H.; McGlynn, K.A.; Byrne, C.; Sampson, J.; Botelho, J.C.; Calafat, A.M.; Rusiecki, J. A Nested Case-Control Study of Serum Per- and Polyfluoroalkyl Substances and Testicular Germ Cell Tumors among, U.S. Air Force Servicemen. Environ Health Perspect. 2023, 131, 77007. [Google Scholar] [CrossRef] [PubMed]
- Chang, V.C.; Rhee, J.; Berndt, S.I.; Moore, S.C.; Freedman, N.D.; Jones, R.R.; Silverman, D.T.; Gierach, G.L.; Hofmann, J.N.; Purdue, M.P. Serum perfluorooctane sulfonate and perfluorooctanoate and risk of postmenopausal breast cancer according to hormone receptor status: An analysis in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Int J Cancer. 2023, 153, 775–782. [Google Scholar] [CrossRef] [PubMed]
- Rhee, J.; Barry, K.H.; Huang, W.Y.; Sampson, J.N.; Hofmann, J.N.; Silverman, D.T.; Calafat, A.M.; Botelho, J.C.; Kato, K.; Purdue, M.P.; Berndt, S.I. A prospective nested case-control study of serum concentrations of per- and polyfluoroalkyl substances and aggressive prostate cancer risk. Environ Res. 2023, 228, 115718. [Google Scholar] [CrossRef] [PubMed]
- Madrigal, J.M.; Troisi, R.; Surcel, H.M.; Öhman, H.; Kivelä, J.; Kiviranta, H.; Rantakokko, P.; Koponen, J.; Medgyesi, D.N.; Kitahara, C.M.; McGlynn, K.A.; Sampson, J.; Albert, P.S.; Ward, M.H.; Jones, R.R. Prediagnostic serum concentrations of per- and polyfluoroalkyl substances and risk of papillary thyroid cancer in the Finnish Maternity Cohort. Int J Cancer. 2023. [CrossRef] [PubMed]
- Rena R Jones, Jessica M Madrigal, Rebecca Troisi, Heljä-Marja Surcel, Hanna Öhman, Juha Kivelä, Hannu Kiviranta, Panu Rantakokko, Jani Koponen, Danielle N Medgyesi, Katherine A McGlynn, Joshua Sampson, Paul S Albert, Mary H Ward, Maternal serum concentrations of per- and polyfluoroalkyl substances and childhood acute lymphoblastic leukemia, JNCI: Journal of the National Cancer Institute 2023, djad261. [CrossRef]
- Dong, T.; Peng, Y.; Zhong, N.; Liu, F.; Zhang, H.; Xu, M.; Liu, R.; Han, M.; Tian, X.; Jia, J.; Chang, L.K.; Guo, L.H.; Liu, S. Perfluorodecanoic acid (PFDA) promotes gastric cell proliferation via sPLA2-IIA. Oncotarget. 2017, 8, 50911–50920. [Google Scholar] [CrossRef] [PubMed]
- Lin, H.W.; Feng, H.X.; Chen, L.; Yuan, X.J.; Tan, Z. Maternal exposure to environmental endocrine disruptors during pregnancy is associated with pediatric germ cell tumors. Nagoya J Med Sci. 2020, 82, 323–333. [Google Scholar] [CrossRef]
- Nuno, M. S. Almeida, Yiğitcan Eken, and Angela, K. Wilson. ACS Omega 2021, 6, 15103–15114. [Google Scholar] [CrossRef] [PubMed]
- Villapol, S. Roles of Peroxisome Proliferator-Activated Receptor Gamma on Brain and Peripheral Inflammation. Cell Mol Neurobiol. 2018, 38, 121–132. [Google Scholar] [CrossRef] [PubMed]
- Kirk, A.B.; Michelsen-Correa, S.; Rosen, C.; Martin, C.F.; Blumberg, B. PFAS and Potential Adverse Effects on Bone and Adipose Tissue Through Interactions With PPARγ. Endocrinology 2021, 162, bqab194. [Google Scholar] [CrossRef]
- Behr, A.C.; Lichtenstein, D.; Braeuning, A.; Lampen, A.; Buhrke, T. Perfluoroalkylated substances (PFAS) affect neither estrogen and androgen receptor activity nor steroidogenesis in human cells in vitro. Toxicol Lett. 2018, 291, 51–60. [Google Scholar] [CrossRef]
- Zhiqiang Qiu, Kaili Qu, Feng Luan, Yaquan Liu, Yu Zhu, Yongna Yuan, Hongyu Li, Haixia Zhang, Ying Hai, Chunyan Zhao, Binding specificities of estrogen receptor with perfluorinated compounds: A cross species comparison. Environment International 2020, 134, 105284. [CrossRef]
- Issa, N.T.; Wathieu, H.; Glasgow, E.; Peran, I.; Parasido, E.; Li, T.; Simbulan-Rosenthal, C.M.; Rosenthal, D.; Medvedev, A.V.; Makarov, S.S.; Albanese, C.; Byers, S.W.; Dakshanamurthy, S. A novel chemo-phenotypic method identifies mixtures of salpn, vitamin D3, and pesticides involved in the development of colorectal and pancreatic cancer. Ecotoxicol Environ Saf. 2022, 233, 113330. [Google Scholar] [CrossRef] [PubMed]
- Del Fiore, P.; Cavallin, F.; Mazza, M.; Benna, C.; Monico, A.D.; Tadiotto, G.; Russo, I.; Ferrazzi, B.; Tropea, S.; Buja, A.; Cozzolino, C.; Cappellesso, R.; Nicolè, L.; Piccin, L.; Pigozzo, J.; Chiarion-Sileni, V.; Vecchiato, A.; Menin, C.; Bassetto, F.; Dei Tos, A.P.; Alaibac, M.; Mocellin, S. Per- and polyfluoroalkyl substances (PFAS) exposure in melanoma patients: a retrospective study on prognosis and histological features. Environ Health. 2022, 21, 126. [Google Scholar] [CrossRef] [PubMed]
- Chang, T.K. Activation of pregnane X receptor (PXR) and constitutive androstane receptor (CAR) by herbal medicines. AAPS J. 2009, 11, 590–601. [Google Scholar] [CrossRef] [PubMed]
- Ngan, C.H.; Beglov, D.; Rudnitskaya, A.N.; Kozakov, D.; Waxman, D.J.; Vajda, S. The structural basis of pregnane X receptor binding promiscuity. Biochemistry. 2009, 48, 11572–11581. [Google Scholar] [CrossRef] [PubMed]
- Brylinski, M. Aromatic interactions at the ligand-protein interface: Implications for the development of docking scoring functions. Chem Biol Drug Des. 2018, 91, 380–390. [Google Scholar] [CrossRef] [PubMed]
- Rimac, H.; Grishina, M.; Potemkin, V. Use of the Complementarity Principle in Docking Procedures: A New Approach for Evaluating the Correctness of Binding Poses. J Chem Inf Model. 2021, 61, 1801–1813. [Google Scholar] [CrossRef]
- T. Lai, T.; Eken, Y., & K. Wilson, A. Binding of Per- and Polyfluoroalkyl Substances to the Human Pregnane X Receptor. Environmental Science Technology 2020, 54, 15986–15995. [Google Scholar] [CrossRef] [PubMed]
- Pavek, P. Pregnane X Receptor (PXR)-Mediated Gene Repression and Cross-Talk of PXR with Other Nuclear Receptors via Coactivator Interactions. Front Pharmacol. 2016, 7, 456. [Google Scholar] [CrossRef]
- Kamaraj, R.; Drastik, M.; Maixnerova, J.; Pavek, P. Allosteric Antagonism of the Pregnane X Receptor (PXR): Current-State-of-the-Art and Prediction of Novel Allosteric Sites. Cells 2022, 11, 2974. [Google Scholar] [CrossRef]
- Li, J.; Cao, H.; Feng, H.; Xue, Q.; Zhang, A.; Fu, J. Evaluation of the Estrogenic/Antiestrogenic Activities of Perfluoroalkyl Substances and Their Interactions with the Human Estrogen Receptor by Combining In Vitro Assays and In Silico Modeling. Environ Sci Technol. 2020, 54, 14514–14524. [Google Scholar] [CrossRef] [PubMed]
- Villeneuve, D.L.; Blackwell, B.R.; Cavallin, J.E.; Collins, J.; Hoang, J.X.; Hofer, R.N.; Houck, K.A.; Jensen, K.M.; Kahl, M.D.; Kutsi, R.N.; Opseth, A.S.; Santana Rodriguez, K.J.; Schaupp, C.; Stacy, E.H.; Ankley, G.T. Verification of In Vivo Estrogenic Activity for Four Per- and Polyfluoroalkyl Substances (PFAS) Identified as Estrogen Receptor Agonists via New Approach Methodologies. Environ Sci Technol. 2023, 57, 3794–3803. [Google Scholar] [CrossRef] [PubMed]
- Bafna, D.; Ban, F.; Rennie, P.S.; Singh, K.; Cherkasov, A. Computer-Aided Ligand Discovery for Estrogen Receptor Alpha. Int J Mol Sci. 2020, 21, 4193. [Google Scholar] [CrossRef] [PubMed]
- Calafat, A.M.; Kuklenyik, Z.; Reidy, J.A.; Caudill, S.P.; Tully, J.S.; Needham, L.L. Serum concentrations of 11 polyfluoroalkyl compounds in the u.s. population: data from the national health and nutrition examination survey (NHANES). Environ Sci Technol. 2007, 41, 2237–2242. [Google Scholar] [CrossRef] [PubMed]
- Ehrlich, V.; Bil, W.; Vandebriel, R.; Granum, B.; Luijten, M.; Lindeman, B.; Grandjean, P.; Kaiser, A.M.; Hauzenberger, I.; Hartmann, C.; Gundacker, C.; Uhl, M. Consideration of pathways for immunotoxicity of per- and polyfluoroalkyl substances (PFAS). Environ Health. 2023, 22, 19. [Google Scholar] [CrossRef]
- Grober, O.M.; Mutarelli, M.; Giurato, G.; Ravo, M.; Cicatiello, L.; De Filippo, M.R.; Ferraro, L.; Nassa, G.; Papa, M.F.; Paris, O.; Tarallo, R.; Luo, S.; Schroth, G.P.; Benes, V.; Weisz, A. Global analysis of estrogen receptor beta binding to breast cancer cell genome reveals an extensive interplay with estrogen receptor alpha for target gene regulation. BMC Genomics. 2011, 12, 36. [Google Scholar] [CrossRef]
- Grober, O.M.; Mutarelli, M.; Giurato, G.; Ravo, M.; Cicatiello, L.; De Filippo, M.R.; Ferraro, L.; Nassa, G.; Papa, M.F.; Paris, O.; Tarallo, R.; Luo, S.; Schroth, G.P.; Benes, V.; Weisz, A. Global analysis of estrogen receptor beta binding to breast cancer cell genome reveals an extensive interplay with estrogen receptor alpha for target gene regulation. BMC Genomics. 2011, 12, 36. [Google Scholar] [CrossRef] [PubMed]
- Grober, O.M.; Mutarelli, M.; Giurato, G.; Ravo, M.; Cicatiello, L.; De Filippo, M.R.; Ferraro, L.; Nassa, G.; Papa, M.F.; Paris, O.; Tarallo, R.; Luo, S.; Schroth, G.P.; Benes, V.; Weisz, A. Global analysis of estrogen receptor beta binding to breast cancer cell genome reveals an extensive interplay with estrogen receptor alpha for target gene regulation. BMC Genomics 2011, 12, 36. [Google Scholar] [CrossRef]
- Wärnmark, A.; Wikström, A.; Wright, A.P.; Gustafsson, J.A.; Härd, T. The N-terminal regions of estrogen receptor alpha and beta are unstructured in vitro and show different TBP binding properties. J Biol Chem. 2001, 276, 45939–45944. [Google Scholar] [CrossRef]
- Kowalska, D.; Sosnowska, A.; Bulawska, N.; Stępnik, M.; Besselink, H.; Behnisch, P.; Puzyn, T. How the Structure of Per- and Polyfluoroalkyl Substances (PFAS) Influences Their Binding Potency to the Peroxisome Proliferator-Activated and Thyroid Hormone Receptors—An In Silico Screening Study. Molecules 2023, 28, 479. [Google Scholar] [CrossRef]
- Gim, H.J.; Choi, Y.S.; Li, H.; Kim, Y.J.; Ryu, J.H.; Jeon, R. Identification of a Novel PPAR-γ Agonist through a Scaffold Tuning Approach. Int J Mol Sci. 2018, 19, 3032. [Google Scholar] [CrossRef] [PubMed]
- Wan, M.L.Y.; Co, V.A.; El-Nezami, H. Endocrine disrupting chemicals and breast cancer: a systematic review of epidemiological studies. Crit Rev Food Sci Nutr. 2022, 62, 6549–6576. [Google Scholar] [CrossRef] [PubMed]
- Yilmaz, B.; Terekeci, H.; Sandal, S.; Kelestimur, F. Endocrine disrupting chemicals: exposure, effects on human health, mechanism of action, models for testing and strategies for prevention. Rev Endocr Metab Disord. 2020, 21, 127–147. [Google Scholar] [CrossRef] [PubMed]
- Rao, A.; Douglas, S.C.; Hall, J.M. Endocrine Disrupting Chemicals, Hormone Receptors, and Acne Vulgaris: A Connecting Hypothesis. Cells. 2021, 10, 1439. [Google Scholar] [CrossRef]
- Toporova, L.; Balaguer, P. Nuclear receptors are the major targets of endocrine disrupting chemicals. Mol Cell Endocrinol. 2020, 502, 110665. [Google Scholar] [CrossRef]










| Protein | Ligand | Orthosteric Docking score | Allosteric Docking score |
|---|---|---|---|
| Farnesoid X Receptor | Chenodeoxycholic | -9.4 | -6.4 |
| Estrogen Receptor | Estradiol | -9.4 | -6.5 |
| Retinoic Acid | Tretinoin | -9.1 | -5.9 |
| PPARG | 15-deoxy-Δ-12,14-Prostaglandin | -8.2 | -4.9 |
| Transthyretin | Triiodothyronine | -8 | -5.3 |
| DTXSID | CASRN | Preferred Name | Classification |
|---|---|---|---|
| DTXSID20816403 | 61547-75-9 | N,N'-Bis[2-(1,1,2,2-tetrafluoro-2-phenylethyl)phenyl]urea | Perfluorocarboxamide |
| DTXSID201033555 | 49924-57-0 | 1-(9H-Fluoren-2-yl)-perfluoro-1-butanone O-[(perfluorobutyl)sulfonyl]oxime | Perfluoroalkane sulfonamido substances |
| DTXSID60371061 | 231953-37-0 | 1-Benzoyl-3,5-bis(heptafluoropropyl)pyrazole | Perfluorocarboxamide |
| DTXSID401026885 | NOCAS_1026885 | 4-Fluoro-N-[1-(4-fluorophenyl)-1-hydroxy-3-(2,2,3,3-tetrafluoro-1,4-benzodioxin-6-yl)propan-2-yl]naphthalene-1-carboxamide | Perfluoroethers |
| DTXSID90776848 | 1555-24-4 | 2,5-Bis(pentadecafluoroheptyl)-1,3,4-oxadiazole | Perfluorooxadiazole |
| DTXSID50238598 | 915-76-4 | 2,4,6-Tris(heptafluoropropyl)-1,3,5-triazine | Perfluorotriazine |
| DTXSID80198893 | 5086-79-3 | 1,3-Bis(2-phenyl-1,3,4-oxadiazol-5-yl)perfluoropropane | Perfluorooxadiazole |
| DTXSID50290777 | 4368-75-6 | 3,3'-(1,1,2,2,3,3-hexafluoropropane-1,3-diyl)bis[5-(pentafluoroethyl)-1,2,4-oxadiazole] | Perfluorooxadiazole |
| DTXSID601035822 | NOCAS_1035822 | Perfluoro-13-(pentafluoro-lambda6-sulfanyl)-1-tridecanesulfonic acid | Perfluoroalkane sulfonic acid |
| DTXSID30896453 | 862130-87-8 | 2-Chloro-4-fluoro-N-(3-{[4-(1,1,1,2,3,3,3-heptafluoropropan-2-yl)-2,6-dimethylphenyl]carbamoyl}phenyl)benzamide | Perfluorocarboxamide |
| DTXSID60896168 | 151707-04-9 | 1,1'-[1,3-Phenylenebis(oxy)]bis[3-(tridecafluorohexyl)benzene] | Perfluoroether |
| DTXSID30897041 | 57912-15-9 | (Perfluoropropyl)-2-(2-phenylhydrazinylidene)ethanal phenylhydrazone | perfluoro something nitrogen |
| DTXSID90896459 | 862130-95-8 | 2,3,6-Trifluoro-N-(3-{[4-(1,1,1,2,3,3,3-heptafluoropropan-2-yl)-2,6-dimethylphenyl]carbamoyl}phenyl)benzamide | Perfluorocarboxamide |
| DTXSID601020695 | 786629-35-4 | 4-((Henicosafluorodecyl)oxy)benzenesulfonic acid | Perfluoroether and Perfluoro sulfonic acid |
| DTXSID00768057 | 132877-69-1 | 1,4-Bis(heptadecafluorooctyl)benzene | Perfluoroalkanes |
| DTXSID | Preferred Name | CASRN | Docking Score |
|---|---|---|---|
| DTXSID40881335 | Perfluoroperhydrobenzyl tetralin | 116265-66-8 | -14.7 |
| DTXSID60881337 | Perfluoro(4a-(cyclohexylmethyl)decahydronaphthalene) | 125061-94-1 | -14.5 |
| DTXSID101023399 | Cyclohexane, 1,1,2,2,3,3,4,4,5,5,6-undecafluoro-6-(1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heneicosafluorodecyl)- | 87667-00-3 | -13.6 |
| DTXSID701036930 | 2-(Perfluoroeicosanyl)ethane-1-sulfonic acid | – | -13.4 |
| DTXSID60895499 | Hexatetracontafluorodocosane | 1127427-64-8 | -13.4 |
| DTXSID901009913 | Perfluorooctadecanesulfonic acid | 51604-60-5 | -13.4 |
| DTXSID40798070 | 2,2'-Dimethoxy-5,5'-bis(tridecafluorohexyl)-1,1'-biphenyl | 658709-63-8 | -13.4 |
| DTXSID301033158 | Perfluorohenicosanoic acid | – | -13.3 |
| DTXSID901026642 | Tritriacontafluoroheptadecanoate | – | -13.2 |
| DTXSID00768057 | 1,4-Bis(heptadecafluorooctyl)benzene | 132877-69-1 | -13.2 |
| DTXSID00379561 | Methyl perfluorooctadecanoate | 16753-33-6 | -13.2 |
| DTXSID301034649 | 1-Hydroxy-18:2 fluorotelomer sulfonic acid | – | -13.2 |
| DTXSID1047029 | Perfluorotetradecahydrophenanthrene | 306-91-2 | -13.2 |
| DTXSID10880471 | (1H,1H-Perfluoro-16-methylheptadecyl)oxirane | 54009-79-9 | -13.2 |
| DTXSID7070218 | (Perfluorooctadecyl)ethyl 2-propenoate | 65104-64-5 | -13.2 |
| DTXSID | Preferred Name | CASRN | Docking Score |
|---|---|---|---|
| DTXSID70597457 | Hexatriacontafluorotetracosahydrocoronene | 51344-02-06 | -10.4 |
| DTXSID60881337 | Perfluoro(4a-(cyclohexylmethyl)decahydronaphthalene) | 125061-94-1 | -9.9 |
| DTXSID40881335 | Perfluoroperhydrobenzyl tetralin | 116265-66-8 | -9.8 |
| DTXSID90984683 | Hexacosafluorohexadecahydrofluoranthene | 662-28-2 | -9.8 |
| DTXSID501041016 | Cyclohexanecarboxamide, N,N'-[4-(phenylazo)-1,3-phenylene]bis[1,2,2,3,3,4,4,5,5,6,6-undecafluoro- (9CI) | 548470-06-0 | -9.6 |
| DTXSID1047029 | Perfluorotetradecahydrophenanthrene | 306-91-2 | -9.6 |
| DTXSID90380005 | Perfluoroperhydrofluorene | 0307-08-04 | -9.4 |
| DTXSID601006972 | Perfluoro-N-(4-methylcyclohexyl)piperidine | 86630-50-4 | -9 |
| DTXSID70880119 | Perfluoro-1,2-bis(perfluorocyclohexyl)ethane | 306-99-0 | -9 |
| DTXSID30952942 | Icosafluorododecahydroacenaphthylene | 0307-07-03 | -8.9 |
| DTXSID40880121 | Perfluoro-2-methyldecalin | 306-95-6 | -8.8 |
| DTXSID10449906 | Peroxide, bis[(undecafluorocyclohexyl)carbonyl] | 203255-90-7 | -8.8 |
| DTXSID30897561 | 1-(Trifluoromethyl)perfluorodecalin | 306-92-3 | -8.7 |
| DTXSID80893316 | Perfluoro-5,5'-bis(trifluoromethyl)-1,1'-bicyclohexyl | 105462-77-9 | -8.7 |
| DTXSID10539058 | 1,1,2,2,3,3,4,4,6,6,7,7,8,8,9,9,10,10,10a-Nonadecafluorodecahydropyrido[1,2-a]azepine | 95827-25-1 | -8.7 |
| DTXSID | CASRN | IUPAC Name | Binding Affinity (Kcal/Mol) |
|---|---|---|---|
| DTXSID501041016 | 548470-06-0 | Cyclohexanecarboxamide, N,N'-[4-(phenylazo)-1,3-phenylene]bis[1,2,2,3,3,4,4,5,5,6,6-undecafluoro- (9CI) | 13.5 |
| DTXSID401026885 | NOCAS_1026885 | 4-Fluoro-N-[1-(4-fluorophenyl)-1-hydroxy-3-(2,2,3,3-tetrafluoro-1,4-benzodioxin-6-yl)propan-2-yl]naphthalene-1-carboxamide | -13.1 |
| DTXSID60881337 | 125061-94-1 | Perfluoro(4a-(cyclohexylmethyl)decahydronaphthalene) | -12.6 |
| DTXSID701026989 | NOCAS_1026989 | 1-[3-Fluoro-1-methyl-2-oxo-3-(trifluoromethyl)indol-5-yl]-3-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-2,4-dioxopyrimidine-5-carboxylic acid | -12.4 |
| DTXSID70896735 | 146304-71-4 | 3,3'-(1,4-Phenylene)bis[5-(tridecafluorohexyl)-1,2,4-oxadiazole] | -12.1 |
| DTXSID10896198 | 446043-85-2 | 1~5~,4~5~-Bis(tridecafluorohexyl)-1~2~,2~2~:2~5~,3~2~:3~5~,4~2~-quaterthiophene | -12.1 |
| DTXSID90984683 | 662-28-2 | Hexacosafluorohexadecahydrofluoranthene | -12 |
| DTXSID70597457 | 51344-02-6 | Hexatriacontafluorotetracosahydrocoronene | -12 |
| DTXSID801026875 | NOCAS_1026875 | 4-[2-[4-[3,3,4,4,5,5-Hexafluoro-2-[6-[2-(4-methoxyphenyl)ethenyl]-2-methyl-1-benzothiophen-3-yl]cyclopenten-1-yl]-3,5-dimethylthiophen-2-yl]ethenyl]benzonitrile | -12 |
| DTXSID60896264 | 919489-99-9 | 3-(Pentadecafluoroheptyl)-5-(pentafluorophenyl)-1,2,4-oxadiazole | -12 |
| DTXSID40881335 | 116265-66-8 | Perfluoroperhydrobenzyl tetralin | -12 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).